Iodixanol Pharmacokinetics in Children
- 1 May 2001
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Cardiology
- Vol. 22 (3) , 223-227
- https://doi.org/10.1007/s002460010208
Abstract
The objective of this report was to study the elimination pharmacokinetics of iodixanol in children. Iodixanol (Visipaque®, Nycomed Inc., Wayne, PA, USA) is a new iso-osmolar iodinated radiocontrast agent. We hypothesized that elimination of this agent would be dependent on age-related differences in renal clearance. Seven centers enrolled 43 patients. Cardiac catheterization was performed in 41 patients and cranial computed tomography in 2. Patients were entered into 5 age groups: newborn to k el). Data were complete for 40 patients, showing mean k el significantly lower in newborn to −1, mean ± standard deviation [SD]): newborn to <2 months 0.185 ± 0.060, 2 to <6 months, 0.256 ± 0.046, 6 months to <1 year 0.299 ± 0.042, 1 to 6 months of age that is comparable to normal adults. Prolonged elimination in children <6 months of age is related to renal immaturity.Keywords
This publication has 0 references indexed in Scilit: